MedCity News November 27, 2024
Several healthcare leaders are supporting the Biden-Harris administration’s proposed rule to expand Medicare and Medicaid coverage of GLP-1 medications for obesity treatment.
Several healthcare leaders are showing their support for the Biden-Harris Administration’s new proposed rule that would expand coverage of GLP-1s for those with Medicare and Medicaid.
Medicare and Medicaid currently cover GLP-1s like Ozempic and Wegovy for diabetes, but Medicare is prohibited from covering them for weight loss while only 13 state Medicaid programs do. The proposal, meanwhile, aims to cover the drugs for obesity as well. According to a White House fact sheet, the proposal could support 3.4 million Medicare enrollees and reduce out-of-pocket costs for these medications by 95% for some beneficiaries. In addition, 4 million...
Today's Sponsors
Today's Sponsor